Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 13/20 | 0.69 |
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990852 | 0.83 | ALOX5 (0.59) | ALOX5GAAHTTALDH1A1KDM4E | |
| SCHEMBL2982978 | 0.83 | ALOX5 (0.73) | ALOX5GAAHTTALDH1A1EPHX2 | |
| SCHEMBL2982793 | 0.83 | ALOX5 (0.98) | ALOX5GAAHTTALDH1A1EPHX2 | |
| SCHEMBL2989990 | 0.82 | ALOX5 (0.72) | ALOX5GAAHTTALDH1A1ADORA1 | |
| SCHEMBL2986701 | 0.82 | ALOX5 (1.00) | ALOX5GAAHTTALDH1A1EPHX2 | |
| SCHEMBL2990310 | 0.82 | ALOX5 (1.00) | ALOX5GAAHTTALDH1A1EPHX2 | |
| SCHEMBL2988782 | 0.79 | ALOX5 (0.74) | ALOX5GAAHTTALDH1A1EPHX2 | |
| SCHEMBL13464236 | 0.79 | ADORA1 (0.73) | ALOX5GAAALDH1A1KDM4EADORA1 | |
| SCHEMBL2977837 | 0.78 | ADORA1 (0.76) | ALOX5GAAALDH1A1KDM4EADORA1 | |
| SCHEMBL13464369 | 0.78 | ALOX5 (0.55) | ALOX5GAAHTTALDH1A1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173930-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-07-08 | — | — | US | claimed |
| WO-2008016648-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | claimed |
| US-20100173930-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-07-08 | — | — | US | disclosed |
| WO-2008016648-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173930-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | ALOX5 3248/4885GAA 820/4885HTT 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.